Drug intelligence / Profile preview

Vivatlac Baby

Development stage: Phase 2
Lead developer: President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Vivatlac Baby is a multi-strain synbiotic product designed for the management of infantile colic. It contains a combination of nine probiotic bacterial strains, including six *Lactobacillus* species and three *Bifidobacterium* species, along with prebiotic components. The product aims to modulate the gut microbiome to reduce crying behavior and other symptoms associated with colic in infants. It was evaluated in a clinical trial conducted by The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz, comparing its efficacy to simethicone in infants aged 3 to 6 weeks.

Brand names: Vivatlac Baby

Beyond the preview

Go deeper on Vivatlac Baby.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivatlac Baby.

Explore the full profile